ciltacabtagene autoleucel
janssen
['multiplemyeloma', 'cartitude1', 'carvykti', 'janssen']
#janssen reported longer-term data from #cartitude1 study demonstrate continued deep and durable responses to #carvykti (#ciltacabtageneautoleucel) in heavily pretreated patients with #relapsed or #refractory #multiplemyeloma #asco22 
Follow top-line development in the oncology commercial domain. Gain entry to KOL discussions, including both medical professionals and business leaders.